FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409123721> ?p ?o ?g. }

• W2409123721 endingPage "12" @default.
• W2409123721 startingPage "1503" @default.
• W2409123721 abstract "This paper includes the results of imaging and kinetic studies on two kinds of In-111-labeled monoclonal antibodies (MoAbs), 96.5 and ZME 018, which are known to have capability of recognizing different surface antigens present in malignant melanoma cells. These MoAbs were supplied by Hybritech Inc. through Teijin Ltd. The former MoAb (96.5) was used on 11 cases of malignant melanoma and one case of basal cell carcinoma, and the latter MoAb (ZME 018) was used on 6 cases of malignant melanoma and one case of basal cell carcinoma. As for the malignant melanoma, the results obtained from both patients groups were compared to each other. Twenty-four out of 31 lesions in the former group and 9 (including 2 occult lesions) out of 10 lesions in the latter group were visualized. However, these positive ratios can not be compared to each other because of the very small number of the lesions in the latter group. One basal cell carcinoma each from both groups were faintly visualized. Distribution patterns of these In-111-labeled MoAbs were similar to each other. Except for the first two cases in the former group, labeling efficiencies were 94.3 +/- 0.7% with 96.5 and 92.0 +/- 0.6% with ZME 018. Urinary excretions on the 1st day were 8.3 +/- 0.9% with the former and 9.3 +/- 0.3% with the latter. However, there was no statistical difference. Following the 1st day, these values changed at the level of several per cent from the 2nd to 4th day, showing a subtle and gradual rise and slightly lower values for In-111-ZME 018. But, again, there were no statistical differences. Whole body retention curves in both groups were similar to each other, and blood clearance curves were also found similar in both groups. HAMA titers were checked in all patients and were found elevated after the administration in most of the cases. Although the number of patients tested in this series is small, especially with In-111-ZME 018, both MoAbs labeled with In-111 seem to be equally capable of visualizing malignant melanoma. Possibility of the treatment of malignant melanoma with this kind of technique was also discussed." @default.
• W2409123721 created "2016-06-24" @default.
• W2409123721 creator A5003064049 @default.
• W2409123721 creator A5016675309 @default.
• W2409123721 creator A5076317422 @default.
• W2409123721 creator A5087141377 @default.
• W2409123721 date "1989-12-01" @default.
• W2409123721 modified "2023-09-27" @default.
• W2409123721 title "[Radioimmunoimaging of malignant melanoma with In-111-labeled monoclonal antibodies 96.5 and ZME 018]." @default.
• W2409123721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2622081" @default.
• W2409123721 hasPublicationYear "1989" @default.
• W2409123721 type Work @default.
• W2409123721 sameAs 2409123721 @default.
• W2409123721 citedByCount "0" @default.
• W2409123721 crossrefType "journal-article" @default.
• W2409123721 hasAuthorship W2409123721A5003064049 @default.
• W2409123721 hasAuthorship W2409123721A5016675309 @default.
• W2409123721 hasAuthorship W2409123721A5076317422 @default.
• W2409123721 hasAuthorship W2409123721A5087141377 @default.
• W2409123721 hasConcept C126322002 @default.
• W2409123721 hasConcept C142724271 @default.
• W2409123721 hasConcept C147483822 @default.
• W2409123721 hasConcept C159654299 @default.
• W2409123721 hasConcept C185592680 @default.
• W2409123721 hasConcept C203014093 @default.
• W2409123721 hasConcept C2777658100 @default.
• W2409123721 hasConcept C2778024521 @default.
• W2409123721 hasConcept C2778804307 @default.
• W2409123721 hasConcept C2779306644 @default.
• W2409123721 hasConcept C3019992690 @default.
• W2409123721 hasConcept C502942594 @default.
• W2409123721 hasConcept C542903549 @default.
• W2409123721 hasConcept C71924100 @default.
• W2409123721 hasConcept C77411442 @default.
• W2409123721 hasConceptScore W2409123721C126322002 @default.
• W2409123721 hasConceptScore W2409123721C142724271 @default.
• W2409123721 hasConceptScore W2409123721C147483822 @default.
• W2409123721 hasConceptScore W2409123721C159654299 @default.
• W2409123721 hasConceptScore W2409123721C185592680 @default.
• W2409123721 hasConceptScore W2409123721C203014093 @default.
• W2409123721 hasConceptScore W2409123721C2777658100 @default.
• W2409123721 hasConceptScore W2409123721C2778024521 @default.
• W2409123721 hasConceptScore W2409123721C2778804307 @default.
• W2409123721 hasConceptScore W2409123721C2779306644 @default.
• W2409123721 hasConceptScore W2409123721C3019992690 @default.
• W2409123721 hasConceptScore W2409123721C502942594 @default.
• W2409123721 hasConceptScore W2409123721C542903549 @default.
• W2409123721 hasConceptScore W2409123721C71924100 @default.
• W2409123721 hasConceptScore W2409123721C77411442 @default.
• W2409123721 hasIssue "12" @default.
• W2409123721 hasLocation W24091237211 @default.
• W2409123721 hasOpenAccess W2409123721 @default.
• W2409123721 hasPrimaryLocation W24091237211 @default.
• W2409123721 hasRelatedWork W181405725 @default.
• W2409123721 hasRelatedWork W1977416344 @default.
• W2409123721 hasRelatedWork W2018997336 @default.
• W2409123721 hasRelatedWork W2029145496 @default.
• W2409123721 hasRelatedWork W2176780488 @default.
• W2409123721 hasRelatedWork W2410356130 @default.
• W2409123721 hasRelatedWork W2476973230 @default.
• W2409123721 hasRelatedWork W2892392007 @default.
• W2409123721 hasRelatedWork W311765538 @default.
• W2409123721 hasRelatedWork W2978971495 @default.
• W2409123721 hasVolume "26" @default.
• W2409123721 isParatext "false" @default.
• W2409123721 isRetracted "false" @default.
• W2409123721 magId "2409123721" @default.
• W2409123721 workType "article" @default.